Revvity Inc. stock gains on Human Cell Design deal and recent rally

Published on 09/20/2026 at 20:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revvity Inc. stock jumped 9.1 percent to USD 140.19 as of September 20, 2026 on optimism around its planned Human Cell Design acquisition. The shares have gained more than 15 percent over the past week, outpacing the broader healthcare sector.

Labor mit Wissenschaftlerin an Sequenziergerät und Reagenzflaschen — Fotorealistisches Life-Sciences-Labor zeigt Revvity Inc. (ISIN US76155R1086) mit automatisiertem Sequenziergerät und Reagenzien, Illustration mit AI erstellt.

Revvity Inc. stock (ISIN US76155R1086) has attracted attention after closing at USD 140.19 on the New York Stock Exchange on September 20, 2026, up 9.1 percent from the prior session, as investors responded to a mix of acquisition news and momentum in its life sciences portfolio.

Stock jumps on Human Cell Design acquisition plan

According to IT BOLTWISE on September 20, 2026, Revvity Inc. shares rose by 9.1 percent to USD 140.19 in New York trading as investors welcomed the company’s planned acquisition of French biotech firm Human Cell Design, which specializes in human cell models for metabolic diseases such as diabetes and obesity.

As Tradingkey reports on September 20, 2026, the planned Human Cell Design deal is expected to add advanced human pancreatic beta cell models to Revvity’s life sciences portfolio, potentially strengthening its position in GLP-1 drug discovery and screening and opening up additional applications in regenerative medicine and cell therapy.

Momentum builds with double-digit weekly gains

The same move is part of a broader rally: over the most recent five trading sessions, Revvity Inc. stock has gained about 15.4 percent, making it one of the top healthcare performers in the S&P 500 during the week, according to Seeking Alpha.

In a separate performance snapshot, iMaster highlights Revvity Inc. as a top health care gainer with a cumulative five-day return of 16.93 percent, illustrating how quickly sentiment has turned in favor of the stock after recent consolidation.

Expectations for the next quarterly report

Looking ahead, investors are already focusing on the company’s upcoming quarterly figures. According to IT BOLTWISE on September 20, 2026, market consensus for Revvity’s next quarter points to earnings per share of USD 1.28 and revenue of USD 702.56 million, compared with USD 1.18 in EPS and USD 699.08 million in revenue in the same quarter a year earlier, implying EPS growth of 8.5 percent and a revenue increase of 0.5 percent year over year.

Those expectations are echoed by research commentary from Zacks, which projects quarterly earnings of USD 1.28 per share for Revvity Inc. and notes the implied 8.5 percent year-on-year increase as a sign of improving profitability despite only modest expected top-line growth.

Analyst stance and insider activity

On the rating side, Revvity Inc. currently carries a Buy-equivalent recommendation, with Zacks assigning the shares a Rank 2 (Buy) as of September 20, 2026, reflecting the firm’s view that near term earnings trends and estimate revisions remain favorable.

As a counterpoint for investors watching governance and insider confidence, Simply Wall St reports that Senior Vice President of Global Operations Tajinder Vohra recently sold approximately USD 1.0 million worth of Revvity shares at an average price of USD 141, with no recorded insider purchases over the past three months, which may temper some of the enthusiasm around the recent price surge.

Stock level and trading details

Per recent New York Stock Exchange data, Revvity Inc. stock closed at USD 140.19 on September 20, 2026, after a 9.1 percent increase from its previous close, and ranked among the strongest health care names over the latest week; over that period, the shares gained about 15.4 percent, moving significantly ahead of the broader health care sector.